Intraocular pressure elevation from topical difluprednate use

Optometry

Volumn 81, Issue 12, 2010, Pages 658-662

  Meehan, Kelly ^a   Vollmer, Lori ^b   Sowka, Joseph ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Anterior uveitis; Difluprednate; Durezol ; Glaucoma; Inflammation; Scleritis; Steroid response

Indexed keywords

DIFLUPREDNATE; DRUG DERIVATIVE; EYE DROPS; FLUPREDNISOLONE; GLUCOCORTICOID;

AFRICAN AMERICAN; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; EMULSION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; MALE; MIDDLE AGED; SCLERITIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AFRICAN AMERICANS; EMULSIONS; FEMALE; FLUPREDNISOLONE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; SCLERITIS; UVEITIS, ANTERIOR;

EID: 78649403445     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.optm.2010.09.001     Document Type: Article

References (14)

1. Bikowski J., Radhakrishnan P., Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 2006, 5(2):125-130.
2. Korenfeld M., Silverstein S., Cook D., et al. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg 2009, 35(1):26-34.
3. Carnahan M., Goldstein D. Management Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Opthalmol 2000, 11:478-483.
4. Hussar D.A. New drugs: Clevidipine butyrate, difluprednate, and tetrabenazine. J Am Pharm Assoc. 2003 2008, 48(6):815-821.
5. Jones R., Rhee D.J. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006, 17(2):163-167.
6. Tripathi R.C., Tripathi B.J. Functional anatomy of the anterior chamber angle. Duane's biomedical foundations of ophthalmology. Vol. 1 1989, 1-88. JB Lippincott Co., Philadelphia, PA. W.W. Tasman, E.A. Jaeger (Eds.).
7. Jamal K.N., Callanan D.G. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol 2009, 3:381-390.
8. Yamaguchi M., Yasueda S., Isowaki A., et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm 2005, 301(1-2):121-128.
9. Abelson M.B., Washburn S. The downside of tear preservatives. Rev Opthalmol 2002, 9(5):102-106.
10. Diederich S., Scholz T., Eigendorff E., et al. Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases. Horm Metab Res 2004, 36(6):423-429.
11. Dunne J.A., Jacobs N., Morrison A., et al. Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol 1985, 69(2):120-125.
12. Ohno S, Mochizuki M, Usui M, et al. A phase III noninferiority study of difluprednate ophthalmic emulsion 0.05% in the treatment of anterior uveitis. Poster presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 6-10, 2007; Ft. Lauderdale, FL. Poster B808, Program 3904.
13. Mochizuki M, Ohno S, Usui M, et al. A phase III open-label clinical study of difluprednate ophthalmic emulsion 0.05% in the treatment of severe refractory anterior uveitis. Poster presented at: The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 6-10, 2007; Ft. Lauderdale, FL, USA. Poster B809, Program 3905.
14. Sirion Therapeutics, Inc. Tampa, FL. A phase III multicenter, randomized, double-masked study of the safety and efficacy of difluprednate 0.05% ophthalmic emulsion compared to prednisolone acetate 1% ophthalmic suspension in the treatment of endogenous anterior uveitis Dec; 2008. Data on file.